{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:00:10Z","timestamp":1771884010772,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-026-04175-3","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T08:47:19Z","timestamp":1771836439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Circulating cell-free DNA and circulating tumor DNA as a prognostic biomarker in metastatic spine disease, is there a role?"],"prefix":"10.1007","volume":"49","author":[{"given":"Hayley A.","family":"Granberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas M.","family":"Bardeesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua H.","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Damante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugce","family":"Kutuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua D.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Ladd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri S.","family":"Khalsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanus","family":"Viljoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Grossbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"4175_CR1","unstructured":"Ziu EVV, Mesfin FB (2023) Spinal Metastasis. Treasure Island (FL): StatPearls Publishing; Updated August 14, 2023"},{"key":"4175_CR2","unstructured":"Jayarangaiah AKA, Theetha Kariyanna P (2023) Bone Metastasis. Treasure Island (FL): StatPearls Publishing; Updated July 31, 2023. Accessed July 17, 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507911\/"},{"issue":"19","key":"4175_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194599","volume":"14","author":"J Litak","year":"2022","unstructured":"Litak J, Czy\u017cewski W, Szymoniuk M et al (2022) Biological and clinical aspects of metastatic spinal tumors. Cancers 14(19):4599","journal-title":"Cancers"},{"issue":"42","key":"4175_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta17420","volume":"17","author":"P Sutcliffe","year":"2013","unstructured":"Sutcliffe P, Connock M, Shyangdan D, Court R, Kandala NB, Clarke A (2013) A systematic review of evidence on malignant spinal metastases: natural history and technologies for identifying patients at high risk of vertebral fracture and spinal cord compression. Health Technol Assess 17(42):1\u2013274. https:\/\/doi.org\/10.3310\/hta17420","journal-title":"Health Technol Assess"},{"issue":"Suppl 1","key":"4175_CR5","doi-asserted-by":"publisher","first-page":"i5","DOI":"10.1093\/nop\/npaa046","volume":"7","author":"JT Wewel","year":"2020","unstructured":"Wewel JT, O\u2019Toole JE (2020) Epidemiology of spinal cord and column tumors. Neurooncol Pract 7(Suppl 1):i5\u2013i9. https:\/\/doi.org\/10.1093\/nop\/npaa046","journal-title":"Neurooncol Pract"},{"key":"4175_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215477","author":"AJA Freitas","year":"2021","unstructured":"Freitas AJA, Causin RL, Varuzza MB (2021) Molecular biomarkers predict pathological complete response of neoadjuvant chemotherapy in breast cancer patients: review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13215477","journal-title":"Cancers (Basel)"},{"key":"4175_CR7","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.wneu.2022.10.053","volume":"169","author":"VB Chakravarthy","year":"2023","unstructured":"Chakravarthy VB, Schachner B, Amin A et al (2023) Long-term clinical outcomes of patients with colorectal cancer with metastatic epidural spinal cord compression treated with hybrid therapy (surgery followed by stereotactic body radiation therapy). World Neurosurg 169:e89\u2013e95. https:\/\/doi.org\/10.1016\/j.wneu.2022.10.053","journal-title":"World Neurosurg"},{"issue":"4","key":"4175_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2144\/btn-2018-0093","volume":"65","author":"JC Yeo","year":"2018","unstructured":"Yeo JC, Lim CT (2018) Potential of circulating biomarkers in liquid biopsy diagnostics. Biotechniques 65(4):187\u2013189. https:\/\/doi.org\/10.2144\/btn-2018-0093","journal-title":"Biotechniques"},{"issue":"224","key":"4175_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3007094","journal-title":"Sci Transl Med"},{"issue":"1","key":"4175_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00876-y","volume":"9","author":"A Bartolomucci","year":"2025","unstructured":"Bartolomucci A, Nobrega M, Ferrier T et al (2025) Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol 9(1):84. https:\/\/doi.org\/10.1038\/s41698-025-00876-y","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"4175_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35320-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Cheng Z, Dong M et al (2022) Tumor fractions deciphered from circulating cell-free DNA methylation for cancer early diagnosis. Nat Commun 13(1):7694. https:\/\/doi.org\/10.1038\/s41467-022-35320-3","journal-title":"Nat Commun"},{"issue":"7","key":"4175_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/14737159.2016.1184974","volume":"16","author":"MR Openshaw","year":"2016","unstructured":"Openshaw MR, Page K, Fernandez-Garcia D, Guttery D, Shaw JA (2016) The role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring. Expert Rev Mol Diagn 16(7):751\u20135. https:\/\/doi.org\/10.1080\/14737159.2016.1184974","journal-title":"Expert Rev Mol Diagn"},{"key":"4175_CR13","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.2147\/cmar.S243320","volume":"12","author":"Y Zhong","year":"2020","unstructured":"Zhong Y, Fan Q, Zhou Z, Wang Y, He K, Lu J (2020) Plasma cfDNA as a potential biomarker to evaluate the efficacy of chemotherapy in gastric cancer. Cancer Manag Res 12:3099\u20133106. https:\/\/doi.org\/10.2147\/cmar.S243320","journal-title":"Cancer Manag Res"},{"issue":"1","key":"4175_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS et al (2017) Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun 8(1):1324. https:\/\/doi.org\/10.1038\/s41467-017-00965-y","journal-title":"Nat Commun"},{"issue":"20","key":"4175_CR15","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.Ccr-15-0584","volume":"21","author":"JS Frenel","year":"2015","unstructured":"Frenel JS, Carreira S, Goodall J et al (2015) Serial next-generation sequencing of circulating cell-free DNA evaluating tumor clone response to molecularly targeted drug administration. Clin Cancer Res 21(20):4586\u201396. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-0584","journal-title":"Clin Cancer Res"},{"key":"4175_CR16","doi-asserted-by":"publisher","unstructured":"Wyatt AW, Annala M, Aggarwal R et al (2017) Concordance of Circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer. J Natl Cancer Inst Dec 1(12). https:\/\/doi.org\/10.1093\/jnci\/djx118","DOI":"10.1093\/jnci\/djx118"},{"issue":"1","key":"4175_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61818-1","volume":"10","author":"J Knuever","year":"2020","unstructured":"Knuever J, Weiss J, Persa OD et al (2020) The use of circulating cell-free tumor DNA in routine diagnostics of metastatic melanoma patients. Sci Rep 10(1):4940. https:\/\/doi.org\/10.1038\/s41598-020-61818-1","journal-title":"Sci Rep"},{"key":"4175_CR18","doi-asserted-by":"publisher","unstructured":"Conteduca V, Scarpi E, Rossi A et al Association of changing bone metastatic (mets) patterns with dynamics of Circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2022\/02\/20 40(6_suppl):152\u2013152. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.152","DOI":"10.1200\/JCO.2022.40.6_suppl.152"},{"issue":"1","key":"4175_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-85797-z","volume":"11","author":"X Zhou","year":"2021","unstructured":"Zhou X, Li C, Zhang Z et al (2021) Kinetics of plasma cfDNA predicts clinical response in non-small cell lung cancer patients. Sci Rep 11(1):7633. https:\/\/doi.org\/10.1038\/s41598-021-85797-z","journal-title":"Sci Rep"},{"key":"4175_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj Mar 29:372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"Bmj Mar"},{"issue":"3","key":"4175_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10549-025-07740-4","volume":"212","author":"G Bader","year":"2025","unstructured":"Bader G, Quintanilha JCF, Veney D et al (2025) Utility of plasma circulating DNA tumor fraction in bone-only metastatic breast cancer: a real-world outcomes study. Breast Cancer Res Treat 212(3):475\u2013486. https:\/\/doi.org\/10.1007\/s10549-025-07740-4","journal-title":"Breast Cancer Res Treat"},{"key":"4175_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110364","volume":"197","author":"Z Bal\u00e1zs","year":"2024","unstructured":"Bal\u00e1zs Z, Balermpas P, Ivankovi\u0107 I et al (2024) Longitudinal cell-free DNA characterization by low-coverage whole-genome sequencing in patients undergoing high-dose radiotherapy. Radiother Oncol 197:110364. https:\/\/doi.org\/10.1016\/j.radonc.2024.110364","journal-title":"Radiother Oncol"},{"issue":"1","key":"4175_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03017-z","volume":"21","author":"J Chiu","year":"2023","unstructured":"Chiu J, Su F, Joshi M et al (2023) Potential value of ctDNA monitoring in metastatic HR + \/HER2\u2009\u2212\u2009breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial. BMC Med 21(1):306. https:\/\/doi.org\/10.1186\/s12916-023-03017-z","journal-title":"BMC Med"},{"key":"4175_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf107","author":"V Conteduca","year":"2025","unstructured":"Conteduca V, Scarpi E, Rossi A et al (2025) Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer. Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf107","journal-title":"Oncologist"},{"issue":"1","key":"4175_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45475-w","volume":"15","author":"NM Fonseca","year":"2024","unstructured":"Fonseca NM, Maurice-Dror C, Herberts C et al (2024) Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun 15(1):1828. https:\/\/doi.org\/10.1038\/s41467-024-45475-w","journal-title":"Nat Commun"},{"issue":"2","key":"4175_CR26","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","volume":"32","author":"MJM Magbanua","year":"2021","unstructured":"Magbanua MJM, Swigart LB, Wu HT et al (2021) Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival. Ann Oncol 32(2):229\u2013239. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.007","journal-title":"Ann Oncol"},{"issue":"3","key":"4175_CR27","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2018.02.013","volume":"74","author":"N Mehra","year":"2018","unstructured":"Mehra N, Dolling D, Sumanasuriya S et al (2018) Plasma cell-free DNA concentration and outcomes from Taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA). Eur Urol 74(3):283\u2013291. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.013","journal-title":"Eur Urol"},{"issue":"5","key":"4175_CR28","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.21037\/tlcr-21-100","volume":"10","author":"CK Park","year":"2021","unstructured":"Park CK, Oh HJ, Kim MS et al (2021) Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res 10(5):2103\u20132117. https:\/\/doi.org\/10.21037\/tlcr-21-100","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"4175_CR29","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/1878-0261.13188","volume":"16","author":"R Sabatier","year":"2022","unstructured":"Sabatier R, Vicier C, Garnier S et al (2022) Circulating tumor DNA predicts efficacy of a dual AKT\/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB\/II study. Mol Oncol 16(10):2057\u20132070. https:\/\/doi.org\/10.1002\/1878-0261.13188","journal-title":"Mol Oncol"},{"issue":"10","key":"4175_CR30","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/1878-0261.13178","volume":"16","author":"EL Symonds","year":"2022","unstructured":"Symonds EL, Pedersen SK, Yeo B et al (2022) Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1\/IKZF1. Mol Oncol 16(10):2031\u20132041. https:\/\/doi.org\/10.1002\/1878-0261.13178","journal-title":"Mol Oncol"},{"issue":"15","key":"4175_CR31","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1078-0432.Ccr-22-2998","volume":"29","author":"SH Tolmeijer","year":"2023","unstructured":"Tolmeijer SH, Boerrigter E, Sumiyoshi T et al (2023) Early on-treatment changes in circulating tumor DNA fraction and response to Enzalutamide or Abiraterone in metastatic castration-resistant prostate cancer. Clin Cancer Res 29(15):2835\u20132844. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2998","journal-title":"Clin Cancer Res"},{"key":"4175_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2017.10.029","volume":"88","author":"S Valpione","year":"2018","unstructured":"Valpione S, Gremel G, Mundra P et al (2018) Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients. Eur J Cancer 88:1\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.029","journal-title":"Eur J Cancer"},{"issue":"2","key":"4175_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/jdv.16766","volume":"35","author":"R V\u00e1raljai","year":"2021","unstructured":"V\u00e1raljai R, Elouali S, Lueong SS et al (2021) The predictive and prognostic significance of cell-free DNA concentration in melanoma. J Eur Acad Dermatol Venereol 35(2):387\u2013395. https:\/\/doi.org\/10.1111\/jdv.16766","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"4175_CR34","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/s2213-2600(18)30264-9","volume":"6","author":"Z Wang","year":"2018","unstructured":"Wang Z, Cheng Y, An T et al (2018) Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med 6(9):681\u2013690. https:\/\/doi.org\/10.1016\/s2213-2600(18)30264-9","journal-title":"Lancet Respir Med"},{"issue":"3","key":"4175_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.4143\/crt.2023.268","volume":"55","author":"DW Lee","year":"2023","unstructured":"Lee DW, Lim Y, Kim HP et al (2023) Circulating tumor DNA dynamics and treatment outcome of regorafenib in metastatic colorectal cancer. Cancer Res Treat 55(3):927\u2013938. https:\/\/doi.org\/10.4143\/crt.2023.268","journal-title":"Cancer Res Treat"},{"issue":"4","key":"4175_CR36","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/1724600819854452","volume":"34","author":"Y Ye","year":"2019","unstructured":"Ye Y, Luo Z, Shi D (2019) Use of cell free DNA as a prognostic biomarker in non-small cell lung cancer patients with bone metastasis. Int J Biol Markers 34(4):381\u2013388. https:\/\/doi.org\/10.1177\/1724600819854452","journal-title":"Int J Biol Markers"},{"issue":"1","key":"4175_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"4175_CR38","doi-asserted-by":"publisher","unstructured":"Granberg HA, Martins Coelho VP Jr., Palmer JD, Chakravarthy VB (2024) Letter: exploring cell-free DNA as a biomarker for assessing tumor burden in metastatic spine disease. J Neurooncol 166(2):377\u2013378. https:\/\/doi.org\/10.1007\/s11060-024-04560-2","DOI":"10.1007\/s11060-024-04560-2"},{"key":"4175_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1355887","volume":"15","author":"J Xu","year":"2024","unstructured":"Xu J, Gao H, Guan X et al (2024) Circulating tumor DNA: from discovery to clinical application in breast cancer. Front Immunol 15:1355887. https:\/\/doi.org\/10.3389\/fimmu.2024.1355887","journal-title":"Front Immunol"},{"issue":"1","key":"4175_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0134-x","volume":"5","author":"J Fares","year":"2020","unstructured":"Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y (2020) Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 5(1):28. https:\/\/doi.org\/10.1038\/s41392-020-0134-x","journal-title":"Signal Transduct Target Ther"},{"key":"4175_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2020.00855","volume":"11","author":"IO Velegzhaninov","year":"2020","unstructured":"Velegzhaninov IO, Belykh ES, Rasova EE, Pylina YI, Shadrin DM, Klokov DY (2020) Radioresistance, DNA damage and DNA repair in cells with moderate overexpression of RPA1. Front Genet 11:855. https:\/\/doi.org\/10.3389\/fgene.2020.00855","journal-title":"Front Genet"},{"issue":"18","key":"4175_CR42","doi-asserted-by":"publisher","first-page":"29963","DOI":"10.18632\/oncotarget.16265","volume":"8","author":"CM Nickson","year":"2017","unstructured":"Nickson CM, Moori P, Carter RJ, Rubbi CP, Parsons JL (2017) Misregulation of DNA damage repair pathways in HPV-positive head and neck squamous cell carcinoma contributes to cellular radiosensitivity. Oncotarget 8(18):29963\u201329975. https:\/\/doi.org\/10.18632\/oncotarget.16265","journal-title":"Oncotarget"},{"key":"4175_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13039-019-0429-1","volume":"12","author":"AE Tijhuis","year":"2019","unstructured":"Tijhuis AE, Johnson SC, McClelland SE (2019) The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity. Mol Cytogenet 12:17. https:\/\/doi.org\/10.1186\/s13039-019-0429-1","journal-title":"Mol Cytogenet"},{"key":"4175_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.767340","volume":"9","author":"S Chen","year":"2021","unstructured":"Chen S, Yang M, Zhong N et al (2021) Quantified CIN score from cell-free DNA as a novel noninvasive predictor of survival in patients with spinal metastasis. Front Cell Dev Biol 9:767340. https:\/\/doi.org\/10.3389\/fcell.2021.767340","journal-title":"Front Cell Dev Biol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04175-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04175-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04175-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:03:32Z","timestamp":1771880612000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04175-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04175-3","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"6 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required for this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors have no relevant financial or non-financial conflicts of interests to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}